Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction
Immatics $110 million follow-on offering
We advised Immatics on the offering of shares
Gamida Cell $20 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Solid Biosciences $75 million common stock PIPE offering
The financing is taking place concurrently with the company’s acquisition of AavantiBio
EDAP TMS $23 million follow-on offering
The ADSs are listed on the Nasdaq Global Market
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Allakos $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Medtronic Global Holdings €3.5 billion notes offering
The investment-grade notes were issued in four tranches
Alignment Healthcare $132.75 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Roivant Sciences $400 million at-the-market offering
We advised the company on an SEC-registered at-the-market offering